ClinicalTrials.gg
CompletedNCT00451360ECHODIAHUpdated Jul 25, 2008

Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip

A Phase 3 interventional study of diacerein in Hip Osteoarthritis, sponsored by Laboratoires NEGMA. Completed at 25 sites in France. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-07-25.

Sponsored by Laboratoires NEGMA (part of Wockhardt) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Osteoarthritis, Hip with a site in France — 10 open to participants now, 16 under way, none of them phase 3. Osteoarthritis, Hip · France.

Enrollment
4th of 20
500 · median 130
Started
1993
the only one that year
Phase 3
6 of 38
none open now
Registered
4th of 38
by date

Among the 38 studies in Osteoarthritis, Hip with a site in France, this one is the 4th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 1993, is one of 6 in phase 3, and was the 4th registered.

Osteoarthritis, Hip

641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

10 of the 38 studies in Osteoarthritis, Hip with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Osteoarthritis, Hip with a site in France, or all of them as a file.
02

Study summary

We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical trial in patients with hip osteoarthritis in order to:

  • evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis
  • to investigate the potential structure-modifying effect of diacerein in patients with hip osteoarthritis

This study compare also after ten years the percentage of patients in each treatment group who require a hip replacement surgery

03

Conditions studied

  • Hip Osteoarthritis

Browse trials for

Keywords

  • Diacerein
  • Hip osteoarthritis
  • Structure-modifying effect / Chondromodulating effect
  • Double blind study
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients fulfilling the American College of Rheumatology criteria for the diagnosis of hip osteoarthritis.
  • Lequesne algofunctional index of at list 3 points.
  • Radiographic criterion for inclusion: joint space width (JSW) between 1 mm and 3 mm. If the JSW exceeded 3 mm, it had to be at least 0.5 mm thinner than JSW of the contra lateral hip, measured at its narrowest point.

Exclusion criteria

Exclusion Criteria:

  • Intraarticular injection or arthroscopy of the hip during the three months prior to inclusion in the study.
  • Any systemic or intraarticular as well as other potential symptom-modifying drugs for osteoarthritis were not allowed during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
500 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Joint space measurement

Secondary outcomes

  1. Requirement of hip replacement surgery after ten years

  2. Tolerability

07

Study locations

25 sites
  • Hôpital Nord
    Amiens, 80030, France
  • Hôpital Pellegrin
    Bordeaux, 33076, France
  • Hôpital Ambroise Paré
    Boulogne, 92100, France
  • CHU cote de Nacre
    Caen, 14033, France
  • Hôpital Mondor
    Créteil, 94000, France
  • Hôpital Général
    Dijon, 21000, France
  • CHU
    Grenoble, 38043, France
  • Hôpital Roger Salengro
    Lille, 59037, France
  • CHRU Dupuytren
    Limoges, 87042, France
  • Hôpital de la Timone
    Marseille, 13 385, France
  • Hôpital Lapeyronie
    Montpellier, 34295, France
  • Hôpital de l'Archet
    Nice, 6202, France
  • Hôpital Cochin, clinique de rhumatologie
    Paris, 74014, France
  • Paris, 75011, France
  • Hôpital Cochin
    Paris, 75014, France
  • Hôpital Leopold Bellan
    Paris, 75674, France
  • CH Lyon Sud
    Pierre Bénite, 69495, France
  • CHU Lyon Sud
    Pierre Bénite, 69495, France
  • Hôpital de la Milétrie
    Poitiers, 86 021, France
  • CHR
    Rennes, 35000, France
  • Hôpitam de Bois Guillaume
    Rouen, 76031, France
  • Hôpital de Hautepierre
    Strasbourg, 67098, France
  • CHU de Rangueil
    Toulouse, 31403, France
  • CHU Trousseau
    Tours, 37044, France
  • CHU de Brabois
    Vandoeuvre les Nancy, 54511, France
08

References and documents

Publications

  • Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M; ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001 Nov;44(11):2539-47. doi: 10.1002/1529-0131(200111)44:113.0.co;2-t. PubMed 11710710 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 1993 and a completion of Apr 1997. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2007
First posted
Mar 23, 2007
Start
Mar 1993
CompletionActual
Apr 1997
Last update
Jul 25, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00451360
Lead sponsor
Laboratoires NEGMA
First posted
Mar 23, 2007
Start date
Mar 1993
Completion
Apr 1997
Last update
Jul 25, 2008

Study contacts

DOUGADOS Maxime
principal investigator · Scientific committee
Michel LEQUESNE
principal investigator · Scientific committee
Bernard MAZIERE
principal investigator · Scientific committee
Eric VIGNON
principal investigator · Scientific committee
Laurent BERDAH
principal investigator · Scientific committee
Minh NGUYEN
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacerein

Start the discussion